Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) EBITDA Margin (2016 - 2025)

Cytokinetics (CYTK) has disclosed EBITDA Margin for 16 consecutive years, with 407.68% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 407.68% in Q4 2025 year-over-year; TTM through Dec 2025 was 518.43%, a N/A change, with the full-year FY2025 number at 893.61%, down 245091.0% from a year prior.
  • EBITDA Margin was 407.68% for Q4 2025 at Cytokinetics, up from 10274.16% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1129.45% in Q2 2024 to a low of 34084.13% in Q3 2023.
  • A 5-year average of 8472.31% and a median of 5700.8% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: tumbled -2838333bps in 2023, then surged 1594490bps in 2024.
  • Cytokinetics' EBITDA Margin stood at 78.29% in 2021, then plummeted by -8738bps to 6919.32% in 2022, then dropped by -18bps to 8135.89% in 2023, then crashed by -309bps to 33290.71% in 2024, then surged by 99bps to 407.68% in 2025.
  • Per Business Quant, the three most recent readings for CYTK's EBITDA Margin are 407.68% (Q4 2025), 10274.16% (Q1 2025), and 33290.71% (Q3 2024).